Consistent with RBM17 expression in LT-HSC, EIF4A2 is also more highly expressed in AML cells with a primitive immunophenotype (Lin-CD34+CD38-CD90+) compared to normal control HSCs (Fig. 6d). This evidence concerns the gene RBM17 and acute myeloid leukemia.